European Journal of Pharmaceutics and Biopharmaceutics Arbel Artzy-Schnirman, Nina Hobi, Nicole Schneider-Daum, Olivier T. Guenat, Claus-Michael Lehr & JosuĂ© Sznitman Abstract With rapid advances in micro-fabrication processes and the availability of biologically-relevant lung cells, the development of lung-on-chip platforms is offering novel avenues for more realistic inhalation assays in pharmaceutical research, and thereby an opportunity…
MoreJournal of Aerosol Medicine and Pulmonary Drug Delivery YaraâMaria Proust, Andreas Stucki, Nicole SchneiderâDaum, ClausâMichael Lehr, Tobias Krebs, Olivier Guenat, Janick Stucki & Nina Hobi Abstract The pulmonary alveolar barrier is one of the largest surfaces of the human body and constantly exposed to aerosols. Yet, the available in vitro systems do poorly represent the…
MoreFrontiers in Bioengineering and Biotechnology. Tissue Engineering and Regenerative Medicine Marcel Felder, Bettina Trueeb, Andreas O. Stucki, Sarah Borcard, Janick D. Stucki, Bruno Schnyder, Thomas Geiser & and Olivier T. Guenat Abstract The lung alveolar region experiences remodeling during several acute and chronic lung diseases, as for instance idiopathic pulmonary fibrosis (IPF), a fatal disease,…
MoreNeoplasia Colin C. TiĂšche, Yanyun Gao, Elias D. BĂŒhrer, Nina Hobi, Sabina A. Berezowska, Kurt Wyler, LaurĂšne Froment, Stefan Weis, Ren-Wang Peng, RĂ©my Bruggmann, Primo SchĂ€r, Michael A. Amrein, Sean R. R. Hal, Patrick Dorn, Gregor Kocher, Carsten Riether, Adrian Ochsenbein, Ralph A. Schmid & Thomas M. Marti Abstract Cell lines are essential tools to…
MoreAngiogenesis Soheila Zeinali, Colette A Bichsel, Nina Hobi, Manuela Funke, Thomas M Marti, Ralph A Schmid, Olivier T Guenat, Thomas Geiser Abstract Idiopathic pulmonary fibrosis is characterized by a progressive scarring and stiffening of the peripheral lung tissue that decreases lung function. Over the course of the disease, the lung microvasculature undergoes extensive remodeling. There…
MoreToxicology Letters Andreas O. Stucki, Giulia Raggi, Serena Sigrist, Pauline Zamprogno, Nicole Schneider-Daum, Claus Michael-Lehr, Hanno Huwer, Janick D. Stucki, Nina Hobi & Olivier T. Guenat Abstract Introduction: The pulmonary alveolar barrier is one of the largest entry ports for xenobiotics into the body and consists of a thin barrier of epithelial and endothelial cells.…
MoreToxicology Letters Nuria Roldan, Aude Rapet, Andreas O. Stucki, Giulia Raggi, Kleanthis Fytianos, Thomas Geiser, Nina Hobi & Olivier T. Guenat Abstract Acute lung injury (ALI) is a complex lung disease in which inflammation plays a central role. The disruption of the alveolar epithelial-endothelial barrier together with an exacerbated inflammatory response lead to influx of…
MoreScientific Reports Janick D. Stucki, Nina Hobi, Artur Galimov, Andreas O. Stucki, Nicole Schneider-Daum, Claus-Michael Lehr, Hanno Huwer, Manfred Frick, Manuela Funke-Chambour, Thomas Geiser & Olivier T. Guenat Abstract Organs-on-chips have the potential to improve drug development efficiency and decrease the need for animal testing. For the successful integration of these devices in research and…
MoreBiomicrofluidics Olivier T. Guenat & François Berthiaume Abstract In the last decade, the advent of microfabrication and microfluidics and an increased interest in cellular mechanobiology have triggered the development of novel microfluidic-based platforms. They aim to incorporate the mechanical strain environment that acts upon tissues and in-vivo barriers of the human body. This article reviews…
More